German Pharma Balks As Second HTA Retrospective Assessment Includes Orphan Drugs
This article was originally published in The Pink Sheet Daily
Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.
You may also be interested in...
Germany’s pharmaceutical sector reforms represent a mixed bag for industry, with the price freeze set to continue, while rebate levels to health insurers are slashed.
With the German drug price freeze set to continue, the pharmaceutical industry wants to see at least an inflation-linked rise in prices and the abandonment of HTA for older products.
Germany’s new grand coalition government includes a health minister with no background in health care.